Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
June 30, 2023 08:25 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
June 26, 2023 08:25 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
June 15, 2023 12:44 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
May 31, 2023 10:38 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
May 11, 2023 07:45 ET
|
Reneo Pharmaceuticals, Inc.
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif.,...
Reneo Announces Pricing of Public Offering of Common Stock
May 03, 2023 23:36 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of...
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 03, 2023 16:01 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of...
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 27, 2023 07:30 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
March 14, 2023 07:30 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...